This Women Health Stock Gets Analyst Downgrade On ‘Approvability Issues, Restructuring’
HC Wainwright has downgraded ObsEva SA (NASDAQ:OBSV) from a Buy to Neutral without a price target. Late last month, the FDA notified…
Analyst Hikes Price Target, Expects Rockwell Medical To Take Steps To Improve Debt Position
HC Wainwright has increased the price target on Rockwell Medical Inc (NASDAQ:RMTI) from $3 to $8, with a Buy rating, reflecting a 1-for-11…
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
Last week, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine, Qdenga, was approved in Indonesia for individuals six to 45 years of age.…
Neurocrine Biosciences Buys UK-Based Hormone Therapy Player
Neurocrine Biosciences Inc (NASDAQ:NBIX) has agreed to pay £48.3 million for the U.K. hormone therapy group, Diurnal Group Plc. The 27.5p share…
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
The regulatory authority in Japan has approved AstraZeneca plc’s (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination for…
Jounce Therapeutics Shares Fall After Disappointing Mid-Stage Lung Cancer Trial Data
Jounce Therapeutics Inc (NASDAQ:JNCE) reported topline data from the randomized Phase 2 SELECT trial evaluating vopratelimab, combined with pimivalimab in immunotherapy…
Outlook Therapeutics Shares Pop After Filing US Application For Its Lead Eye Disease Candidate
Outlook Therapeutics Inc (NASDAQ:OTLK) has re-submitted its marketing application to the FDA, seeking approval for ONS-5010 for wet age-related macular degeneration…
Connect Biopharma’s Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile
Connect Biopharma Holdings Limited (NASDAQ:CNTB) has completed its first-in-human Phase 1 study of CBP-174 in healthy adults. CBP-174, a highly selective,…
Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold
The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.
Amid Federal Probes, Morgan Stanley’s Internal Lawyer To Oversee Block Trading Desk
Morgan Stanley (NYSE:MS) has ordered one of its internal lawyers to be on its U.S. equity syndicate desk to…